# Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Study · id `cardio:ct-nct05193578` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05193578](<https://clinicaltrials.gov/study/NCT05193578>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05193578

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

## Technical summary

Registry record NCT05193578. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-03-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 154 participants (enrolled count; ClinicalTrials.gov record NCT05193578, source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT05193578, source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)
- Primary completion: 2024-03-18 (actual) (ClinicalTrials.gov record NCT05193578, source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)
- Completion: 2024-05-01 (actual) (ClinicalTrials.gov record NCT05193578, source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)
- Countries: Denmark (ClinicalTrials.gov record NCT05193578, source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05193578-2024-07-08`, retrieved 2026-11-18)

## The registry's words

- Brief title: Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
- Acronym: HISTORI
- Condition: Schizophrenia
- Condition: Prediabetic State
- Intervention (Drug): Semaglutide, 1.34 mg/mL
- Intervention (Other): Placebo
- Lead sponsor: Jan Frystyk
- Lead sponsor class: OTHER
- Collaborator: Region Zealand
- Collaborator class: OTHER
- Collaborator: Region of Southern Denmark
- Collaborator class: OTHER
- Collaborator: Steno Diabetes Center Sjaelland
- Collaborator class: OTHER\_GOV
- Collaborator: Steno Diabetes Center Odense
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as a collaborator: Region of Southern Denmark (`cardio:org-region-of-southern-denmark`)
- Registry lists this organization as a collaborator: Steno Diabetes Center Odense (`cardio:org-steno-diabetes-center-odense`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial (`cardio:pubmed-40900607`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 05b29c5c36cb0c09a4805ddefea06758d10cd470ce95cdedd0991ea478a61c44
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
